25 May Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first line ART
Posted at 09:17h
in
Authored by: Lambert Niclot S., George E. C., Pozniak A., White E., Schwimmer C., Jessen H., Johnson M., Dunn D., Perno C. F., Clotet B., Plettenberg A., Blaxhult A., Palmisano L., Wittkop L., Calvez V., Marcelin A. G., Raffi F.
In: JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY 71(4), 2016, p.1056 1062.
http://www.ncbi.nlm.nih.gov/pubmed/26702926